ADMA Biologics Inc. (ADMA) Stock on the Rise Following Announcement of Potential Public Offering

ADMA Biologics Inc. (ADMA) stock prices were up by 8.55% shortly after market trading commenced on October 21st, 2021. This brought the price per share up to USD$1.20 early on in the trading day.

ADMA Stock’s Public Offering

October 20th, 2021 saw ADMA stock announce its intent to offer shares of its common stock for sale in an underwritten public offering. The end-to-end commercial biopharmaceutical company will offer underwriters a 30-day option which will allow them to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering will be subject to market and other conditions, with no guarantees of its completion or of the actual size or terms of the offering.

Allocation of Resources

ADMA stock plans to use the net proceeds generated from the offering to advance the commercial sales of its products that have been approved by the United States Food and Drug Administration. This will be facilitated by the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV. The company will also allocate capital towards the expansion of its plasma collection network, as well as to scale up the manufacturing capacity of its Boca Raton facility. Continuous improvements will be made in order for the company to adhere to current Good Manufacturing Practice (cGMP) compliance. The generated funds will also be put towards the exploration of business development opportunities, as well as general corporate purposes and other capital expenditures.

About ADMA Stock

The company is dedicated to the manufacturing, marketing, and development of specialty plasma-derived biologics. These biologics are focused on the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA stock currently manufactures and markets three plasma derived biologics that have been approved by the United States Food and Drug Administration. These treatments target immune deficiencies and facilitate the prevention of various infectious diseases.

Future Outlook for ADMA

ADMA stock is keen to capitalize on the expanded scope of opportunities afforded to it from the generation of extra capital through its pending offering. The company is taking steps to continue its trajectory of success in a bit to usher in unprecedented growth. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.